XBiotech (XBIT) EBITDA (2014 - 2026)

XBiotech has reported EBITDA for 13 years, with the latest figure at -$6.1 million in Q2 2026.

• On a quarterly basis, EBITDA rose 3.0% year-over-year to -$6.1 million in Q2 2026; TTM through Jun 2026 was -$48.3 million, a 32.15% decrease from a year earlier, with the FY2025 full-year figure at -$55.7 million, down 31.11% from the prior year.
• EBITDA was -$6.1 million for Q2 2026 at XBiotech, up from -$29.8 million in the prior quarter.
• The five-year high for EBITDA was -$6.0 million in Q3 2025, with the low at -$29.8 million in Q4 2025.
• Average EBITDA over 5 years is -$10.4 million, with a median of -$8.5 million recorded in 2023.
• The largest YoY upside for EBITDA was 57.66% in 2025 against a maximum downside of 240.13% in 2025.
• Over 5 years, EBITDA stood at -$8.2 million in 2022, then retreated by 5.22% to -$8.6 million in 2023, then slipped by 1.86% to -$8.7 million in 2024, then plunged by 240.13% to -$29.8 million in 2025, then soared by 79.34% to -$6.1 million in 2026.
• The last three EBITDA figures came in at -$6.1 million (Q2 2026), -$29.8 million (Q4 2025), and -$6.0 million (Q3 2025), per Business Quant data.